Article (Scientific journals)
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT.
Baron, Frédéric; Labopin, Myriam; Tischer, Johanna et al.
2023In Journal of Hematology and Oncology, 16 (1), p. 10
Peer Reviewed verified by ORBi
 

Files


Full Text
s13045-023-01403-x-1.pdf
Publisher postprint (1.12 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
AML; Acute myeloid leukemia; HLA-haploidentical; Mismatched unrelated donor; PTCy; Post-transplant cyclophosphamide; Cyclophosphamide; Humans; Transplantation, Haploidentical/adverse effects; Unrelated Donors; Cyclophosphamide/therapeutic use; Recurrence; Transplantation Conditioning/adverse effects; Retrospective Studies; Graft vs Host Disease/etiology; Graft vs Host Disease/prevention & control; Graft vs Host Disease/drug therapy; Leukemia, Myeloid, Acute/drug therapy; Hematopoietic Stem Cell Transplantation/adverse effects; Cancer Research; Oncology; Molecular Biology; Hematology
Abstract :
[en] The association between graft-versus-host disease (GVHD) occurrence and acute myeloid leukemia (AML) relapse in patients treated with HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HCT) with post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis has remained debated. Here, we addressed this issue in patients with active AML at transplantation. 2-year cumulative incidences of relapse and leukemia-free survival (LFS) were 49% and 32.3%, respectively. There were no associations between acute nor chronic GVHD of any grade and lower relapse incidence. However, grade I acute GVHD was associated with better LFS (HR = 0.71, 95% CI 0.51-0.99, P = 0.04). In contrast, grade III-IV acute (HR = 3.09, 95% CI 1.87-5.12, P < 0.0001) as well as extensive chronic (HR = 3.3, 95% CI 1.81-6.04, P = 0.0001) GVHD correlated with higher nonrelapse mortality leading to lower LFS (HR = 1.36, 95% CI 0.99-1.86, P = 0.056 and HR = 1.97, 95% CI 1.35-2.89, P = 0.0004, respectively). In conclusion, these data suggest a dissociation of graft-versus-leukemia effects from GVHD in patients with active AML treated with PTCy-based Haplo-HCT.
Disciplines :
Hematology
Author, co-author :
Baron, Frédéric  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
Labopin, Myriam;  EBMT Paris Study Office/CEREST-TC, Paris, France ; Department of Hematology, Saint Antoine Hospital, Paris, France ; INSERM UMR 938, Paris, France ; Sorbonne University, Paris, France
Tischer, Johanna;  Department of Internal Medicine III, LMU, University Hospital of Munich, Campus Grosshadern, Munich, Germany
Raiola, Anna Maria;  IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Vydra, Jan;  Institute of Hematology and Blood Transfusion, Prague, Czech Republic
Blaise, Didier;  Programme de Transplantation et d'immunothérapie Cellulaire, Management Sport Cancer Lab, Institut Paoli Calmettes, Aix Marseille University, Marseille, France
Chiusolo, Patrizia;  Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
Stölzel, Friedrich;  University Hospital Dresden, Medizinische Klinik und Poliklinik, TU Dresden, Dresden, Germany ; University Hospital Schleswig-Holstein, Kiel, Germany
Fanin, Renato;  Division of Hematology, Azienda Ospedaliero Universitaria di Udine, Udine, Italy
Chevallier, Patrice;  Dept. D`Hematologie, CHU Nantes, Nantes, France
Nagler, Arnon;  Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel
Ciceri, Fabio;  Haematology and BMT, Ospedale San Raffaele S.R.L., Milan, Italy
Mohty, Mohamad;  EBMT Paris Study Office/CEREST-TC, Paris, France ; Department of Hematology, Saint Antoine Hospital, Paris, France ; INSERM UMR 938, Paris, France ; Sorbonne University, Paris, France
More authors (3 more) Less
Language :
English
Title :
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT.
Publication date :
13 February 2023
Journal title :
Journal of Hematology and Oncology
eISSN :
1756-8722
Publisher :
Springer Science and Business Media LLC, England
Volume :
16
Issue :
1
Pages :
10
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Available on ORBi :
since 17 February 2023

Statistics


Number of views
58 (3 by ULiège)
Number of downloads
21 (1 by ULiège)

Scopus citations®
 
4
Scopus citations®
without self-citations
4
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi